Evaluating the likelihood of pediatric sacral nerve stimulator explantations due to cure or complications: a survival analysis of 13-year institutional cohort - Summary - MDSpire
Advertisement
Evaluating the likelihood of pediatric sacral nerve stimulator explantations due to cure or complications: a survival analysis of 13-year institutional cohort
To analyze long-term outcomes of pediatric patients undergoing sacral nerve modulation (SNM) for refractory bladder bowel dysfunction (BBD) and the reasons for device explantation (removal of the device).
Key Findings:
Out of 129 SNM placements, 47 (36.4%) underwent explantation.
72.3% of explantations were due to symptom resolution (cure), while 27.7% were due to complications.
Median time to explantation was 6.0 years, with a 6-year explantation risk of 36.3% for cure and 13.8% for complications.
94.4% of patients who achieved cure and were followed up post-explantation had sustained symptom resolution.
Interpretation:
The majority of SNM explantations in pediatric patients were due to successful symptom resolution rather than complications, indicating favorable long-term outcomes for this intervention.
Limitations:
Retrospective design may introduce selection bias, potentially skewing the results.
Follow-up response rate was only 52.9%, which may affect the reliability of symptom resolution data.
Conclusion:
SNM is a viable long-term treatment for pediatric BBD, with a significant proportion of patients achieving symptom resolution and successful explantation, supporting its use in clinical practice.
by Jin Kyu Kim, Konrad M. Szymanski, Rosalia Misseri, Shelly J. King, Nikhil V. Batra, Martin Kaefer, Mark P. Cain, Richard C. Rink, Joshua Roth, Pankaj Dangle, Kirstan Meldrum, Benjamin M. Whittam
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 16 - 31.
